CD47 antigen inhibitors - Pipeline Insight, 2022
![](/report_cover/8047/cd47-antigen-inhibitors-pipeline-insight-2022_en.gif)
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “CD47 antigen inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 28+ companies and 28+ pipeline drugs in CD47 antigen inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
CD47 antigen inhibitors: Overview
CD47 (also known as the integrin-associated signal transducer) is a cell surface molecule in the immunoglobulin superfamily that has been reported to bind to several different proteins, including integrins, thrombospondin-1, and most importantly, signal regulatory protein ? (SIRP?), which is a heavily glycosylated transmembrane protein with an immunoreceptor tyrosine-based inhibition motif (ITIM). CD47 occurs in all cells, including platelets. It is an unusual member of the Ig superfamily with a V-like extracellular domain, five membrane-spanning domains, and a short cytoplasmic domain. CD47 inhibition leads to stimulation of phagocytosis of cancer cells by macrophages. Anti-CD47 antibodies enhance the phagocytosis of tumor cells by macrophages by directly blocking the binding of tumor cell-expressing CD47 to macrophage-expressing SIRP?.
Report Highlights
This segment of the CD47 antigen inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CD47 antigen inhibitors Emerging Drugs
Further product details are provided in the report……..
CD47 antigen inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different CD47 antigen inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
CD47 antigen inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses CD47 antigen inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CD47 antigen inhibitors drugs.
CD47 antigen inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “CD47 antigen inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 28+ companies and 28+ pipeline drugs in CD47 antigen inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
CD47 antigen inhibitors: Overview
CD47 (also known as the integrin-associated signal transducer) is a cell surface molecule in the immunoglobulin superfamily that has been reported to bind to several different proteins, including integrins, thrombospondin-1, and most importantly, signal regulatory protein ? (SIRP?), which is a heavily glycosylated transmembrane protein with an immunoreceptor tyrosine-based inhibition motif (ITIM). CD47 occurs in all cells, including platelets. It is an unusual member of the Ig superfamily with a V-like extracellular domain, five membrane-spanning domains, and a short cytoplasmic domain. CD47 inhibition leads to stimulation of phagocytosis of cancer cells by macrophages. Anti-CD47 antibodies enhance the phagocytosis of tumor cells by macrophages by directly blocking the binding of tumor cell-expressing CD47 to macrophage-expressing SIRP?.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence CD47 antigen inhibitors R&D. The therapies under development are focused on novel approaches for CD47 antigen inhibitors.
This segment of the CD47 antigen inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CD47 antigen inhibitors Emerging Drugs
- Magrolimab: Forty Seven, Inc.
- Evorpacept: ALX Oncology
Further product details are provided in the report……..
CD47 antigen inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different CD47 antigen inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on CD47 antigen inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
CD47 antigen inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses CD47 antigen inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CD47 antigen inhibitors drugs.
CD47 antigen inhibitors Report Insights
- CD47 antigen inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing CD47 antigen inhibitors drugs?
- How many CD47 antigen inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CD47 antigen inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CD47 antigen inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for CD47 antigen inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Forty Seven, Inc.
- ALX Oncology
- Shattuck Labs
- EpicentRx
- Waterstone Hanxbio
- Akeso Biopharma
- Trillium Therapeutics Inc.
- Adagene
- Arch Oncology
- ImmuneOncia Therapeutics
- Celgene Corporation
- ImmuneOnco Biopharma
- Light Chain Bioscience
- Trillium Therapeutics Inc
- TG Therapeutics
- MORPHIEX BIOTHERAPEUTICS
- KAHR Medical
- I-MAb Biopharma
- Centessa Pharmaceuticals
- Hanmi Pharm.Co.,Ltd.
- Innovent Biologics
- OSE Immunotherapeutics
- Biocad
- ZAI LAB
- EMulate Therapeutics
- Alector, Inc.
- Sorrento Therapeutics
- Surface Oncology
- QLSF Biotherapeutics
- Ichnos Sciences
- Magrolimab
- Evorpacept
- SL 172154
- RRx-001
- HX 009
- AK 117
- TTI 622
- AL008
- ISB 1442
- STI-6643
- QL401
- SRF231
- SAFE CD47 NEObody
- AO 176
- IMC 002
- ZL-1201
- BCD-106
- CC 90002
- IMM 2505
- BI 765063
- IB1188
- IMM 0306
- NI 1801
- TJC4
- Ontorpacept
- TG-1801
- DSP107
- MBT-001
Introduction
Executive Summary
CD47 antigen inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
CD47 antigen inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Magrolimab: Forty Seven, Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Evorpacept - ALX Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
STI-6643: Sorrento Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
ISB 1442: Ichnos Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
CD47 antigen inhibitors Key Companies
CD47 antigen inhibitors Key Products
CD47 antigen inhibitors- Unmet Needs
CD47 antigen inhibitors- Market Drivers and Barriers
CD47 antigen inhibitors- Future Perspectives and Conclusion
CD47 antigen inhibitors Analyst Views
CD47 antigen inhibitors Key Companies
Appendix
Executive Summary
CD47 antigen inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
CD47 antigen inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Magrolimab: Forty Seven, Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Evorpacept - ALX Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
STI-6643: Sorrento Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
ISB 1442: Ichnos Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
CD47 antigen inhibitors Key Companies
CD47 antigen inhibitors Key Products
CD47 antigen inhibitors- Unmet Needs
CD47 antigen inhibitors- Market Drivers and Barriers
CD47 antigen inhibitors- Future Perspectives and Conclusion
CD47 antigen inhibitors Analyst Views
CD47 antigen inhibitors Key Companies
Appendix